[
  {
    "ts": null,
    "headline": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=54b7859e9d5c478d8dc3a59e78466dbd6c5c6940ddf6ec391c1377515069e2f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733842211,
      "headline": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio",
      "id": 131912403,
      "image": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=54b7859e9d5c478d8dc3a59e78466dbd6c5c6940ddf6ec391c1377515069e2f6"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis initiated with a Neutral at UBS",
    "summary": "UBS initiated coverage of Zoetis (ZTS) with a Neutral rating and $196 price target Zoetis is “reaping the rewards of a relatively unchallenged, multi-year innovation cycle,” while product breadth and vet loyalty have secured the company’s positioning for revenue growth, the analyst tells investors. The firm projects a 6% revenue compound annual growth rate and 7% EBITDA CAGR from 2025-2030, but sees a risk/reward skew that “appears balanced here” and is less convinced investors would be willing",
    "url": "https://finnhub.io/api/news?id=0c9f4abcc5cd9207d401d8e826109f0da3cb8c3b5d3cd7398c745a7668321469",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733841827,
      "headline": "Zoetis initiated with a Neutral at UBS",
      "id": 131912405,
      "image": "https://media.zenfs.com/en/tipranks_452/1e5c62569304a546b8f4bd9cc2d706a2",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "UBS initiated coverage of Zoetis (ZTS) with a Neutral rating and $196 price target Zoetis is “reaping the rewards of a relatively unchallenged, multi-year innovation cycle,” while product breadth and vet loyalty have secured the company’s positioning for revenue growth, the analyst tells investors. The firm projects a 6% revenue compound annual growth rate and 7% EBITDA CAGR from 2025-2030, but sees a risk/reward skew that “appears balanced here” and is less convinced investors would be willing",
      "url": "https://finnhub.io/api/news?id=0c9f4abcc5cd9207d401d8e826109f0da3cb8c3b5d3cd7398c745a7668321469"
    }
  },
  {
    "ts": null,
    "headline": "UBS Initiates Coverage of Zoetis (ZTS) with Neutral Recommendation",
    "summary": "UBS Initiates Coverage of Zoetis (ZTS) with Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=795917d5131a996f2d4268fa094a16e7ae791ba29c14003c5a31f0fb19a8a918",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733832387,
      "headline": "UBS Initiates Coverage of Zoetis (ZTS) with Neutral Recommendation",
      "id": 131900885,
      "image": "",
      "related": "ZTS",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=795917d5131a996f2d4268fa094a16e7ae791ba29c14003c5a31f0fb19a8a918"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis : Announces Global Launch of Vetscan OptiCell™ at VMX 2025",
    "summary": "New point-of-care hematology analyzer, Vetscan OptiCell™, to launch at VMX in Orlando, January 25-29, 2025. The analyzer's innovative combination of viscoelastic focusing and...",
    "url": "https://finnhub.io/api/news?id=7b7f1cdb6f4cf7682d32c9387ecf64f8691fdc2f03eb6ea4ec41b1b93877de50",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733823245,
      "headline": "Zoetis : Announces Global Launch of Vetscan OptiCell™ at VMX 2025",
      "id": 131902035,
      "image": "",
      "related": "ZTS",
      "source": "Finnhub",
      "summary": "New point-of-care hematology analyzer, Vetscan OptiCell™, to launch at VMX in Orlando, January 25-29, 2025. The analyzer's innovative combination of viscoelastic focusing and...",
      "url": "https://finnhub.io/api/news?id=7b7f1cdb6f4cf7682d32c9387ecf64f8691fdc2f03eb6ea4ec41b1b93877de50"
    }
  }
]